CureVac (CVAC) Stock Forecast, Price Target & Predictions
CVAC Stock Forecast
CureVac stock forecast is as follows: an average price target of $29.00 (represents a 743.02% upside from CVAC’s last price of $3.44) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CVAC Price Target
The average price target for CureVac (CVAC) is $29.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $21.00. This represents a potential 743.02% upside from CVAC's last price of $3.44.
CVAC Analyst Ratings
According to 2 Wall Street analysts, CureVac's rating consensus is 'Buy'. The analyst rating breakdown for CVAC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CureVac Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 07, 2023 | Eun Yang | Jefferies | $21.00 | $8.26 | 154.24% | 510.47% |
| Apr 22, 2022 | - | JMP Securities | $37.00 | $16.79 | 120.37% | 975.58% |
The latest CureVac stock forecast, released on Jan 07, 2023 by Eun Yang from Jefferies, set a price target of $21.00, which represents a 154.24% increase from the stock price at the time of the forecast ($8.26), and a 510.47% increase from CVAC last price ($3.44).
CureVac Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.44 | $3.44 | $3.44 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of CureVac stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CureVac's last price of $3.44. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 07, 2023 | Jefferies | - | Buy | Upgrade |
| Nov 17, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
CureVac's last stock rating was published by Jefferies on Jan 07, 2023. The company Upgrade its CVAC rating from "null" to "Buy".
CureVac Financial Forecast
CureVac Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $7.13M | $11.69M | $11.21M | $20.15M | $24.37M | $41.23M | $29.34M | $22.39M | $10.03M | $6.04M | $5.16M |
| Avg Forecast | $22.98M | $21.29M | $19.72M | $18.26M | $9.01M | $3.46M | $8.02M | $10.62M | $38.91M | $17.02M | $20.62M | $9.70M | $17.48M | $20.40M | $17.86M | $22.99M | $4.16M | $23.47M | $12.34M | $12.34M | $3.68M | $53.06M |
| High Forecast | $22.98M | $21.29M | $19.72M | $18.26M | $9.01M | $3.46M | $8.02M | $10.62M | $38.91M | $17.02M | $20.62M | $9.70M | $17.48M | $20.40M | $17.86M | $22.99M | $4.16M | $23.47M | $12.34M | $12.34M | $3.68M | $53.06M |
| Low Forecast | $22.98M | $21.29M | $19.72M | $18.26M | $9.01M | $3.46M | $8.02M | $10.62M | $38.91M | $17.02M | $20.62M | $9.70M | $17.48M | $20.40M | $17.86M | $22.99M | $4.16M | $23.47M | $12.34M | $12.34M | $3.68M | $53.06M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.67% | 0.55% | 1.13% | 1.06% | 9.91% | 1.25% | 1.81% | 0.81% | 1.64% | 0.10% |
CureVac's average Quarter revenue forecast for Jun 23 based on 2 analysts is $20.62M, with a low forecast of $20.62M, and a high forecast of $20.62M. CVAC's average Quarter revenue forecast represents a 189.21% increase compared to the company's last Quarter revenue of $7.13M (Mar 23).
CureVac EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-50.92M | $-126.38M | $-40.41M | $-49.40M | $-4.17M | $96.00K | $-141.56M | $-144.08M | $-105.66M | $-46.25M | $-32.88M |
| Avg Forecast | $-22.98M | $-21.29M | $-19.72M | $-18.26M | $-9.01M | $-3.46M | $-8.02M | $-10.62M | $-38.91M | $-17.02M | $-20.62M | $-9.70M | $-17.48M | $-20.40M | $-17.86M | $-6.24M | $-4.16M | $-23.47M | $-12.34M | $-12.34M | $-3.68M | $-36.80M |
| High Forecast | $-22.98M | $-21.29M | $-19.72M | $-18.26M | $-9.01M | $-3.46M | $-8.02M | $-10.62M | $-38.91M | $-17.02M | $-20.62M | $-9.70M | $-17.48M | $-20.40M | $-17.86M | $-4.99M | $-4.16M | $-23.47M | $-12.34M | $-12.34M | $-3.68M | $-29.44M |
| Low Forecast | $-22.98M | $-21.29M | $-19.72M | $-18.26M | $-9.01M | $-3.46M | $-8.02M | $-10.62M | $-38.91M | $-17.02M | $-20.62M | $-9.70M | $-17.48M | $-20.40M | $-17.86M | $-7.49M | $-4.16M | $-23.47M | $-12.34M | $-12.34M | $-3.68M | $-44.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 5.25% | 7.23% | 1.98% | 2.77% | 0.67% | -0.02% | 6.03% | 11.67% | 8.56% | 12.57% | 0.89% |
1 analysts predict CVAC's average Quarter EBITDA for Mar 22 to be $-6.24M, with a high of $-4.99M and a low of $-7.49M. This is -6597.48% lower than CureVac's previous annual EBITDA (Dec 21) of $96.00K.
CureVac Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-57.42M | $-128.78M | $-47.57M | $-57.58M | $-15.09M | $-1.94M | $-144.02M | $-152.06M | $-113.70M | $-58.15M | $-36.83M |
| Avg Forecast | $-23.99M | $-26.69M | $-31.09M | $-36.60M | $-51.21M | $327.44M | $-62.84M | $-60.43M | $-44.75M | $-50.62M | $-53.80M | $-73.91M | $-67.69M | $-60.02M | $-57.67M | $-22.58M | $-146.16M | $-158.83M | $-190.56M | $-127.71M | $-115.38M | $-41.22M |
| High Forecast | $-23.99M | $-26.69M | $-31.09M | $-36.60M | $-51.21M | $801.49M | $-62.84M | $-60.43M | $-44.75M | $-50.62M | $-53.80M | $-73.91M | $-67.69M | $-60.02M | $-57.67M | $-18.06M | $-146.16M | $-158.83M | $-190.56M | $-127.71M | $-115.38M | $-32.97M |
| Low Forecast | $-23.99M | $-26.69M | $-31.09M | $-36.60M | $-51.21M | $-151.50M | $-62.84M | $-60.43M | $-44.75M | $-50.62M | $-53.80M | $-73.91M | $-67.69M | $-60.02M | $-57.67M | $-27.09M | $-146.16M | $-158.83M | $-190.56M | $-127.71M | $-115.38M | $-49.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 1.90% | 0.79% | 1.00% | 0.67% | 0.01% | 0.91% | 0.80% | 0.89% | 0.50% | 0.89% |
CureVac's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CVAC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
CureVac SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $19.70M | $23.66M | $22.08M | $23.07M | $20.60M | $14.61M | $22.66M | $31.78M | $19.90M | $11.81M | $9.22M |
| Avg Forecast | $32.96M | $30.53M | $28.28M | $26.19M | $12.93M | $4.96M | $11.50M | $15.23M | $55.81M | $24.40M | $29.57M | $13.91M | $25.07M | $29.26M | $25.62M | $32.97M | $5.97M | $33.66M | $17.70M | $17.69M | $5.28M | $10.32M |
| High Forecast | $32.96M | $30.53M | $28.28M | $26.19M | $12.93M | $4.96M | $11.50M | $15.23M | $55.81M | $24.40M | $29.57M | $13.91M | $25.07M | $29.26M | $25.62M | $32.97M | $5.97M | $33.66M | $17.70M | $17.69M | $5.28M | $12.38M |
| Low Forecast | $32.96M | $30.53M | $28.28M | $26.19M | $12.93M | $4.96M | $11.50M | $15.23M | $55.81M | $24.40M | $29.57M | $13.91M | $25.07M | $29.26M | $25.62M | $32.97M | $5.97M | $33.66M | $17.70M | $17.69M | $5.28M | $8.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.42% | 0.94% | 0.75% | 0.90% | 0.62% | 2.45% | 0.67% | 1.80% | 1.12% | 2.24% | 0.89% |
CureVac's average Quarter SG&A projection for Jun 23 is $29.57M, based on 2 Wall Street analysts, with a range of $29.57M to $29.57M. The forecast indicates a 50.06% rise compared to CVAC last annual SG&A of $19.70M (Mar 23).
CureVac EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.68 | $-0.26 | $-0.31 | $-0.08 | $-0.01 | $-0.80 | $-0.84 | $-0.62 | $-0.32 | $-0.20 |
| Avg Forecast | $-0.11 | $-0.12 | $-0.14 | $-0.16 | $-0.23 | $1.46 | $-0.28 | $-0.27 | $-0.20 | $-0.23 | $-0.24 | $-0.33 | $-0.30 | $-0.27 | $-0.26 | $-0.57 | $-0.65 | $-0.71 | $-0.85 | $-0.57 | $-0.51 | $-0.35 |
| High Forecast | $-0.11 | $-0.12 | $-0.14 | $-0.16 | $-0.23 | $3.57 | $-0.28 | $-0.27 | $-0.20 | $-0.23 | $-0.24 | $-0.33 | $-0.30 | $-0.27 | $-0.26 | $-0.57 | $-0.65 | $-0.71 | $-0.85 | $-0.57 | $-0.51 | $-0.35 |
| Low Forecast | $-0.11 | $-0.12 | $-0.14 | $-0.16 | $-0.23 | $-0.68 | $-0.28 | $-0.27 | $-0.20 | $-0.23 | $-0.24 | $-0.33 | $-0.30 | $-0.27 | $-0.26 | $-0.57 | $-0.65 | $-0.71 | $-0.85 | $-0.57 | $-0.51 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 2.25% | 0.97% | 1.21% | 0.14% | 0.02% | 1.13% | 0.99% | 1.09% | 0.62% | 0.58% |
According to undefined Wall Street analysts, CureVac's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CVAC previous annual EPS of $NaN (undefined).
CVAC Forecast FAQ
Is CureVac a good buy?
Yes, according to 2 Wall Street analysts, CureVac (CVAC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CVAC's total ratings.
What is CVAC's price target?
CureVac (CVAC) average price target is $29 with a range of $21 to $37, implying a 743.02% from its last price of $3.44. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CureVac stock go up soon?
According to Wall Street analysts' prediction for CVAC stock, the company can go up by 743.02% (from the last price of $3.44 to the average price target of $29), up by 975.58% based on the highest stock price target, and up by 510.47% based on the lowest stock price target.
Can CureVac stock reach $5?
CVAC's average twelve months analyst stock price target of $29 supports the claim that CureVac can reach $5 in the near future.
What are CureVac's analysts' financial forecasts?
CureVac's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $31.11M (high $31.11M, low $31.11M), average EBITDA is $-31.11M (high $-31.11M, low $-31.11M), average net income is $152.95M (high $627M, low $-326M), average SG&A $44.62M (high $44.62M, low $44.62M), and average EPS is $0.682 (high $2.8, low $-1.453). CVAC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $82.25M (high $82.25M, low $82.25M), average EBITDA is $-82.249M (high $-82.249M, low $-82.249M), average net income is $-118M (high $-118M, low $-118M), average SG&A $117.96M (high $117.96M, low $117.96M), and average EPS is $-0.528 (high $-0.528, low $-0.528).
Did the CVAC's actual financial results beat the analysts' financial forecasts?
Based on CureVac's last annual report (Dec 2022), the company's revenue was $67.42M, which missed the average analysts forecast of $78.73M by -14.37%. Apple's EBITDA was $-223M, beating the average prediction of $-61.982M by 259.94%. The company's net income was $-249M, beating the average estimation of $-208M by 19.75%. Apple's SG&A was $89.41M, missing the average forecast of $112.91M by -20.82%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-1.396 by -5.46%. In terms of the last quarterly report (Mar 2023), CureVac's revenue was $7.13M, missing the average analysts' forecast of $9.7M by -26.51%. The company's EBITDA was $-50.922M, beating the average prediction of $-9.7M by 424.94%. CureVac's net income was $-57.419M, missing the average estimation of $-73.907M by -22.31%. The company's SG&A was $19.7M, beating the average forecast of $13.91M by 41.64%. Lastly, the company's EPS was $-0.27, missing the average prediction of $-0.329 by -18.05%